Recombinant Mouse Membrane-associated progesterone receptor component 2 (Pgrmc2)

What is Pgrmc2 and what protein family does it belong to?

Pgrmc2 (Progesterone Receptor Membrane Component 2) is a member of the Membrane Associated Progesterone Receptor (MAPR) family that includes four proteins: PGRMC1, PGRMC2, Neudesin, and Neuferricin. These proteins share a cytochrome b5-like domain (PFAM00173) and bind heme . Unlike Neudesin and Neuferricin which are soluble and secreted, PGRMC2 possesses a single predicted transmembrane domain, similar to PGRMC1 .

The protein contains a cytochrome b5-like heme/steroid binding domain, although direct evidence for steroid hormone binding is less conclusive than for heme binding. Structurally, Pgrmc2 is designed to function in heme trafficking with medium-low affinity for heme (Kd ~1.4 x 10^-6 M for ferric heme and 5.3 x 10^-6 M for ferrous heme), suggesting it binds heme reversibly rather than serving as a terminal storage protein .

How is Pgrmc2 different from Pgrmc1?

While both Pgrmc1 and Pgrmc2 are heme-binding proteins in the MAPR family with transmembrane domains, they display distinct subcellular localizations and functions:

Evidence suggests a sequential relationship where mitochondria-bound PGRMC1 transfers heme to ER-bound PGRMC2, which subsequently delivers heme to proteins in the ER and nucleus, including heme-responsive transcription factors .

How can researchers generate Pgrmc2 knockout mice?

The generation of conditional Pgrmc2-ablated mice employs Cre-Lox recombination technology through the following methodology:

• Prepare a targeting vector by recombineering, retrieving a 13.6-kb section of the Pgrmc2 genomic sequence containing exons 2 and 3 plus 4 kb of 3′-downstream sequences from bacterial artificial chromosome RP23-2C23 into pPL253 by gap repair .

• Insert a 5′ LoxP site into intron 1 approximately 1.3 kb upstream of exon 2, followed by insertion of Frt-PGFneo-Frt-LoxP into the 3′-downstream sequence approximately 0.9 kb downstream of exon 3 .

• Linearize the vector by NotI digestion, purify, and electroporate into mouse embryonic stem cells derived from F1(129Sv/C57BL6j) blastocysts .

• Culture cells with G418 (150 μg/mL) and ganciclovir (2 μM), then select drug-resistant colonies and screen by nested long-range PCR .

• Use targeted ES cells to generate chimeric mice by aggregation with CD1 morula, then breed chimeric males with ROSA26-Flpe mice to remove the PGKneo cassette, generating Pgrmc2 floxed (Pgrmc2 fl/fl) founder mice .

• Cross these mice with tissue-specific Cre recombinase-expressing mice (e.g., Pgr-cre) to achieve conditional knockout in tissues of interest .

What assays can determine Pgrmc2's heme binding and transfer capabilities?

Several experimental approaches can assess Pgrmc2's interaction with heme:

• In-gel heme transfer assay: Incubate apo-Rev-Erbα with PGRMC2, separate the mixture by native electrophoresis, and stain for both heme and protein. Observation of heme staining in the Rev-Erbα band indicates successful heme transfer from PGRMC2 to apo-Rev-Erbα .

• Heme binding affinity measurements: Spectroscopic analyses to determine Kd values for both ferric and ferrous heme forms (1.4 x 10^-6 M and 5.3 x 10^-6 M respectively for Pgrmc2) .

• Subcellular labile heme assessment: Transfect cells with GFP:hemoprotein peroxidase fusion reporters targeted to specific compartments (mitochondria, ER, cytosol, nuclei). The activity of these reporters directly correlates with the availability of labile heme in each compartment, allowing visualization of heme trafficking defects when Pgrmc2 is manipulated .

• Mutational analysis: Generate heme-binding mutants (e.g., PGRMC2 3xM) to demonstrate the necessity of the heme-binding capability for Pgrmc2's functions in heme transfer .

How does Pgrmc2 facilitate intracellular heme trafficking?

PGRMC2 functions as a critical intracellular heme chaperone in a sophisticated trafficking pathway that allows heme to move from its synthesis site to target proteins throughout the cell. This process involves:

• Heme synthesis completion in mitochondria, where ferrochelatase (FECH) adds iron to protoporphyrin IX .

• Initial transfer of newly synthesized heme from mitochondria to mitochondria-bound PGRMC1 .

• Subsequent transfer from PGRMC1 to ER-bound PGRMC2, acting as an intermediate carrier .

• PGRMC2-mediated delivery of heme to target proteins in the ER and nuclear compartments .

This pathway is evidenced by experiments showing that dual PGRMC1/2 knockdown had no additional effect beyond PGRMC2 knockdown alone on nuclear heme levels, suggesting PGRMC2 acts downstream of PGRMC1 in trafficking endogenously-synthesized heme . The medium-low affinity of PGRMC2 for heme (Kd values in the micromolar range) supports its role in transient binding and transfer rather than terminal storage .

What is the relationship between Pgrmc2 and nuclear transcription factors?

PGRMC2 plays a crucial role in regulating nuclear transcription factors through heme delivery:

• PGRMC2 delivers labile heme to the nucleus, directly affecting heme-responsive transcriptional repressors including Rev-Erbα and BACH1 .

• When PGRMC2 is deleted in tissues like brown fat, labile heme in the nucleus decreases, resulting in increased stability of these transcriptional repressors .

• The altered transcriptional landscape leads to extensive changes in gene expression, particularly affecting mitochondrial function genes .

• Direct heme transfer from PGRMC2 to apo-Rev-Erbα has been demonstrated in vitro, with wild-type PGRMC2 (but not heme-binding mutants) capable of transferring heme to Rev-Erbα .

This transcriptional regulation mechanism explains many of the physiological defects observed in Pgrmc2-deficient models, as these heme-responsive transcription factors control genes involved in cellular metabolism and mitochondrial function.

How does Pgrmc2 deficiency affect adipose tissue function?

Deletion of Pgrmc2 in brown adipose tissue (BAT) results in profound metabolic dysfunction:

These defects are specifically related to PGRMC2's heme-trafficking function, as introduction of wild-type human PGRMC2 into mouse PGRMC2-null brown adipocytes restores mitochondrial bioenergetics and UCP1 levels, while expression of a PGRMC2 heme-binding mutant does not . The thermogenic defect is independent of norepinephrine levels, as the transcriptional response to adrenergic stimulation remains intact despite the functional impairment .

What role does Pgrmc2 play in reproductive physiology?

Conditional ablation of Pgrmc2 in the female reproductive system results in significant fertility defects:

Similar reproductive defects have been observed in both Pgrmc2-null and Pgrmc1/2 double knockout models, suggesting overlapping functions of these proteins in reproductive physiology . The specific mechanisms by which Pgrmc2 supports embryo development and implantation require further investigation but may involve heme-dependent processes in the uterine environment.

Does Pgrmc2 have potential as a therapeutic target in metabolic disease?

Evidence suggests PGRMC2 may be a promising therapeutic target for metabolic disorders:

• Obese-diabetic mice treated with a small-molecule PGRMC2 activator showed substantial improvement of diabetic features, suggesting pharmacological enhancement of PGRMC2 function could ameliorate metabolic dysfunction .

• The critical role of PGRMC2 in adipocyte function, particularly in brown adipose tissue, positions it as a potential target for enhancing energy expenditure and improving metabolic health .

• When fed a high-fat diet, adipose-specific PGRMC2-null mice showed greater metabolic deterioration, implying that boosting PGRMC2 function might protect against diet-induced metabolic disorders .

The specific mechanisms by which PGRMC2 activation improves metabolic parameters require further investigation but likely involve enhanced mitochondrial function and heme-dependent metabolic processes in adipose tissue. Development of selective PGRMC2 modulators could represent a novel approach to treating obesity and diabetes.

What are the most pressing unanswered questions about Pgrmc2 function?

Several critical questions remain regarding Pgrmc2 function:

• Structural determinants of heme binding and transfer: While Pgrmc2 is known to bind and transfer heme, the precise structural mechanisms and protein-protein interfaces involved in this process remain poorly characterized .

• Tissue-specific functions: Pgrmc2 is expressed in multiple tissues, but its function has been primarily studied in adipose tissue and reproductive organs. Its roles in other tissues, particularly the brain and liver, warrant further investigation .

• Relationship to progesterone signaling: Despite its name suggesting a role in progesterone signaling, the connection between Pgrmc2's heme-binding function and potential involvement in steroid hormone pathways remains unclear .

• Therapeutic targeting specificity: Development of selective Pgrmc2 modulators will require better understanding of structural and functional differences between Pgrmc1 and Pgrmc2 to enable isoform-specific targeting .

• Interaction with cellular stress responses: The connection between Pgrmc2-mediated heme trafficking and cellular responses to various stressors, including oxidative stress, represents an important area for future research .

Addressing these questions will require interdisciplinary approaches combining structural biology, genetics, biochemistry, and physiological studies to fully elucidate the mechanisms and significance of Pgrmc2 function.